UNSPSC 51102873: Sulfabenzamide/sulfacetamide/sulfathiazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU300. This VA Drug Class (GU300) classifies this compound as belonging to the group ANTI-INFECTIVES, VAGINAL.

UNSPSC 51102873 Sulfabenzamide/sulfacetamide/sulfathiazole is a Commodity code that shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The three opportunities present in the recent solicitations record address naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which directly specify the sulfonamide antimicrobial compounds named in the code. The mismatch between the code designation and the actual work being solicited suggests this code sees limited application in state and local government purchasing, or that jurisdictions tag pharmaceutical and medical-supply procurements under broader family-level codes rather than this specific Commodity designation.

The recent activity that does appear spans state health agencies and local government purchasing offices. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026; the City of Tampa issued an IFB (26P00145) on March 25, 2026, for medical and first aid supplies supporting the Tampa Fire Department Rescue Division, with a response deadline of March 13, 2026, and an estimated contract value of $700,000.00; Seminole County, Florida solicited an IFB (IFB60459723LAS) on June 30, 2026, for naloxone and safe drug deactivation systems with quarterly deliveries, due July 26, 2023; and the Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capabilities. The geographic spread includes Florida, Texas, Minnesota, and Oregon within the cooperative purchasing framework, though the limited number of relevant opportunities suggests this code warrants monitoring rather than active pursuit at this time.